Global Dilated Cardiomyopathy Therapeutics Market to Decline at a Negative CAGR of 7.0%: Transparency Market Research

ALBANY, N.Y.--()--Transparency Market Research has released a new report titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020”, which forecasts the global dilated cardiomyopathy therapeutics market to decline during the forecast period from 2014 to 2020 at a negative CAGR of 7%. In 2013, Global dilated cardiomyopathy therapeutics market was valued at US$651.0 million and is expected to reach US$328.6 million in 2020.

Browse Report: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Dilated cardiomyopathy (DCM) results due to the dilation of heart muscles, which eventually leads to heart failure. Treatment for DCM includes oral medications and implantable medical devices. Even though the condition is one of the major reasons for heart failure, the global dilated cardiomyopathy therapeutics market is expected to slow down through the forecast period due to patent expirations, potential side effects of the drugs and increasing efficiency of alternative therapies such as gene therapy and implantable medical devices.

Request Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2293

The dilated cardiomyopathy therapeutics market is segmented on the basis of drug class and geography. Among the drugs used for treating the condition, angiotensin converting enzyme (ACE) inhibitors act as the first line of treatment. Factors such as patent expiration of prominent drugs and increasing competition from generic drugs are expected to hinder the sales of ACE inhibitors during the forecast period.

Press Release: http://www.transparencymarketresearch.com/pressrelease/dilated-cardiomyopathy-market.htm

Aldosterone antagonists such as Eplerenone and Spironolactone have gained acceptance and are hence expected to record the highest growth in the forecast period. Doctors prescribe these drugs due to their effectiveness in the treatment of DCM. This creates an opportunity for market players to develop the specific drugs.

Novartis International AG, Merck Co. & Inc., and AstraZeneca plc together account for more than 70% of the dilated cardiomyopathy therapeutics market revenue.

Browse All Pharmaceuticals Market Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About TMR:

Transparency Market Research (TMR) is a U.S. based market intelligence company driven by high-pedigree consultants and researchers. TMR leverages its Syndicated Research, Custom Research, and Market Consulting expertise to help businesses make accurate decisions. TMR’s exclusive blend of quantitative forecasting and trends analysis draws on proprietary data sources and techniques, while their data repository is continuously updated to reflect the latest trends.

Contacts

Transparency Market Research
Mr. Nachiket Ghumare, +1-518-618-1030
USA-Canada Toll Free: 866-552-3453
sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/

Release Summary

Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Contacts

Transparency Market Research
Mr. Nachiket Ghumare, +1-518-618-1030
USA-Canada Toll Free: 866-552-3453
sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/